Press Announcements > FDA approves Xermelo for carcinoid syndrome diarrhea

Press Announcements > FDA approves Xermelo for carcinoid syndrome diarrhea

FDA approves Xermelo for carcinoid syndrome diarrhea

02/28/2017 04:30 PM EST

The U.S. Food and Drug Administration today approved Xermelo (telotristat ethyl) tablets in combination with somatostatin analog (SSA) therapy for the treatment of adults with carcinoid syndrome diarrhea that SSA therapy alone has inadequately controlled.